ERBB2 and breast carcinoma: In this Phase III non-inferiority trial, women with T1N0 breast cancer and ER+PR+HER2- breast cancer with a Grade 1–2 disease treated with breast-conserving surgery and a low-risk PAM-50 score are randomized to receive either endocrine therapy alone or radiation therapy and endocrine therapy.